[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2022091141A1 - An improved process of donepezil hydochloride - Google Patents

An improved process of donepezil hydochloride Download PDF

Info

Publication number
WO2022091141A1
WO2022091141A1 PCT/IN2021/051042 IN2021051042W WO2022091141A1 WO 2022091141 A1 WO2022091141 A1 WO 2022091141A1 IN 2021051042 W IN2021051042 W IN 2021051042W WO 2022091141 A1 WO2022091141 A1 WO 2022091141A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
dimethoxy
dihydro
inden
compound
Prior art date
Application number
PCT/IN2021/051042
Other languages
French (fr)
Inventor
Mafatlal Maganlal PATEL
Vital Mafatlal Patel
Dr. RAMESH CHANDRA SINGH
Dr. JAYRAJSINH P. YADAV
Original Assignee
Vihita Chem Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vihita Chem Private Limited filed Critical Vihita Chem Private Limited
Publication of WO2022091141A1 publication Critical patent/WO2022091141A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Definitions

  • the present invention relates to a process for preparation of 2-((l-benzylpiperidin-4-yl) methyl)-5,6-dimethoxy- 2,3-dihydro- 1H-inden- 1 -one Hydrochloride (Donepezil hydrochloride) of formula I .
  • the present invention also relates to a intermediates of Donepezil, (E)-2-(( 1 -benzylpiperidin-4-yl) methylene)- 5,6-dimethoxy- 2,3-dihydro- 1H- inden-l-one hydrochloride compound of formula V which is further converted to highly pure intermediates of Donepezil, (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- dihydro- 1H-inden- 1 -one compound of formula IV.
  • Donepezil hydrochloride is a useful memory enhancer introduced by the Japanese pharmaceutical company Eisai. Its preparation was described in patent no. EP 296560. In this patent Donepezil was produced by reaction of 5,6-dimethoxy- 1 -indanone with l-benzyl-4- formylpiperidine in the presence of a strong base, such as lithium diisopropylamide followed by reduction of the double bond.
  • a strong base such as lithium diisopropylamide
  • Patent application EP 711756 describes the preparation of Donepezil by reaction of 5,6- dimethoxy- 1 -indanone with pyridin-4-aldehyde to give 5,6-dimethoxy-2-(pyridin-4- yl)methylene indan-l-one further the reaction with benzyl bromide afforded 1 -benzyl -4-(5, 6- dimethoxyindan-l-on-2-ylidene)methylpyridinium bromide. Hydrogenation in the presence of platinum oxide to obtain Donepezil.
  • the inventors have observed that during the condensation reaction of 5,6-dimethoxy-2,3- dihydro- 1 H-i nden- 1 -one compound of formula-II, with 1 -benzylpiperidine -4-carbaldehyde compound of formula-III, for the preparation of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden-l-one compound of formula IV formation of an impurity at 0.47-0.49 RRT occurs about 15% to 10%.
  • the amount of impurity formation varies depending upon reaction conditions, amount of solvent, nature of solvent used.
  • the present invention provides an efficient and industrially advantageous process for the preparation of highly pure donepezil hydrochloride in high yields.
  • present invention provides an improved process for the preparation of highly pure 2-((l-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2, 3 -dihydro- 1H-inden-l -one
  • Hydrochloride (Donepezil HC1) of formula I comprises: a) condensation reaction of 5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula-II with l-benzylpiperidine-4-carbaldehyde compound of formula-III to obtain of (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1 H-inden- 1 - one compound of formula IV ; b) treating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH- inden-l-one compound of formula IV with acid and converting to pharmaceutically acceptable salts and isolating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-
  • present invention provides a process for the preparation of (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one compound of formula IV comprises: a) condensation reaction of 5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula-II with 1 -benzylpiperidine -4-carbaldehyde compound of formula-III; in the presence of phase transfer catalyst and base with methylene dichloride.
  • present invention provides a process for the purification of E’)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one compound of formula IV to remove impurity comprising a) treating the reaction mixture with acid wherein pH is below 1.0; b) treating the reaction mixture with base wherein pH is greater than 11.0; c) repeat step (a) and step (b) up to impurity at 0.49 RRT NMT 0.3 %; d) washing with ketone solvent at 55 -65 °C;
  • present invention provides an isolated compound (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-l 1H-inden-1 -one Hydrochloride compound of formula V
  • FIGURE 1 is a HPLC chromatograph of result of analysis of Crude (E)-2-(( 1 -benzylpiperidin- 4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
  • FIGURE 2 is a HPLC chromatograph of result of analysis of Purification in Ethyl acetate of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
  • FIGURE 3 is a HPLC chromatograph of result of analysis of Purification in Diisopropyl ether of (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one, Compound of Formula IV.
  • FIGURE 4 is a HPLC chromatograph of result of analysis of Purification in Isopropyl acetate (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
  • FIGURE 5 is a HPLC chromatograph of result of analysis of Crude of Example 2 (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one, Compound of Formula IV.
  • FIGURE 6 is a HPLC chromatograph of result of analysis of I st Acid treatment of Example 2 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
  • FIGURE 7 is a HPLC chromatograph of result of analysis of I st Base treatment of Example 2 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
  • FIGURE 8 is a HPLC chromatograph of result of analysis of II nd Acid treatment of Example 2 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one,
  • FIGURE 9 is a HPLC chromatograph of result of analysis of II nd Base treatment of Example
  • FIGURE 10 is a HPLC chromatograph of result of analysis of treatment with Acetone of Example 2 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l- one, Compound of Formula IV.
  • FIGURE 11 is a HPLC chromatograph of result of analysis of Crude of Example 3 (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one, Compound of Formula IV.
  • FIGURE 12 is a HPLC chromatograph of result of analysis of I st Acid treatment of Example
  • FIGURE 13 is a HPLC chromatograph of result of analysis of I st Base treatment of Example
  • FIGURE 14 is a HPLC chromatograph of result of analysis of II nd Acid treatment of Example 3 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one,
  • FIGURE 15 is a HPLC chromatograph of result of analysis of II nd Base treatment of Example 3 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one,
  • FIGURE 16 is a HPLC chromatograph of result of analysis of treatment with Acetone of Example 3 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l- one, Compound of Formula IV.
  • FIGURE 17 is a HPLC chromatograph of result of analysis of crude 2-(( 1 -benzylpiperidin-4- yl)methyl)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one Compound of Formula I
  • FIGURE 18 is a HPLC chromatograph of result of analysis of purified 2-(( 1 -benzylpiperidin- 4-yl) methyl)-5,6-dimethoxy- 2,3-dihydro-lH-inden-l-one Hydrochloride (Donepezil Hydrochloride) of formula I
  • phase-transfer catalyst is a quaternary ammonium salt such as tetra-n-butylammonium chloride, tetra-n-butylammonium bromide (TBAB), and methyltri-n- octylammonium chloride.
  • phase-transfer catalyst is Tetrabutyl ammonium halides, such as tetrabutylammonium bromide (TBAB).
  • organic solvent comprises ethers, alcohols, chlorinated hydrocarbons, esters, ketones, hydrocarbons, polar aprotic solvents, water and mixtures thereof.
  • the isolated (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride compound of formula V was treated with base to obtain (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH- inden-l-one compound of formula IV.
  • acid is selected from hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid or boric acid and base is selected from sodium hydroxide and potassium hydroxide.
  • ketone solvent are 2-pentanone, 3-pentanone, 2-hexanone, methyl isobutyl ketone, 2-heptanone, 3-heptanone, 4-heptanone, diisobutyl ketone, mesityl oxide, phorone, 2- octanone, cyclohexanone, methylcyclohexanone, isophorone, 2,4-pentanedione or 2,5- hexanedione, acetone or methyl ethyl ketone.
  • (E)-2-((l-benzylpiperidin-4- yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1 H-inden-1 -one compound of formula IV is carried out using palladium catalyst in an organic solvent at 0-50° C. preferably at 25-40° C. under 1-5 atmospheric pressure preferably at 4 atmospheric pressure.
  • the organic solvent can be selected from solvent comprises ethers, alcohols, chlorinated hydrocarbons, esters, ketones, hydrocarbons, polar aprotic solvents, water and mixtures thereof and preferably ethyl acetate is used.
  • hydrogenation reactions is carried out using palladium catalyst and it was found that using palladium catalyst with solvent, impurity at RRT 0.32 is substantial controlled depending upon the solvent system used during the reaction.
  • Palladium catalyst can be selected from Palladium oxide, Palladium on carbon and preferably Palladium on carbon is used.
  • the reaction can be accomplished at 0-50°C and preferably at 25-35°C.
  • HPLC high performance liquid chromatography
  • the progress of the reaction is monitored by high performance liquid chromatography (HPLC) and the reaction is stirred till the unreacted Formula IV not more than 0.8%.
  • the reaction mixture is filtered to recover the catalyst.
  • the filtrate is concentrated and crude donepezil is dissolved in aq. Solution of Acid preferably HC1 and washed with organic solvent preferably Ethyl acetate.
  • the aqueous layer is treated with methylene chloride (MDC).
  • MDC methylene chloride
  • the resulting mixture is concentrated and the product obtained is recrystallized from methanol and diisopropyl ether to obtain highly pure donepezil hydrochloride having purity greater than 99.2% preferably greater than 99.9%.
  • stage I impurity is removed from (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride compound of formula V by and further treatment with acid and base of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- di hydro- 1H-inden- 1 -one compound of formula IV.
  • 2,3-dihydro- 1 //-inden- 1 -one compound of formula IV 5.6-dimethoxy-2,3-dihydro-lH-inden-l-one (100g) was dissolved in methylene dichloride (350ml) followed by addition of TBAB (10.0g) cooled to 15 ⁇ 5 temperature, add sodium hydroxide solution 250 ml. l-benzylpiperidine-4-carbaldehyde (126.8g) solution in dichloromethane was added to reaction mass below 20 °C. The temperature of the reaction mass was gradually raised to 40 to 45 °C and was stirred for 6 hours. The reaction mass was concentrated under vacuum.
  • the reaction mass was treated with around 10 % NaOH Solution (200 ml To 220 ml ) and pH was adjusted to not less than 11.5, [Preparation of 10 % NaOH Solution : 20 gm NaOH dissolved in 200 ml of Process Water]
  • the reaction mixture was stirred for 2 to 4hr at 20-45°C and after completion of reaction, the reaction mass was filtered and washed with water.
  • the process of acid and base treatment was repeated up to unknown impurity at 0.47-0.49 RRT was NMT 0.3 %.
  • After the completion of acid base treatment reaction mass was treated with acetone. The temperature of the reaction mass was gradually raised to 55 to 65°C and was stirred for 0.5 hours.
  • EXAMPLE 3 Preparation and Purification of (E , )-2-((l-benzylpiperidin-4-yl)methylene)- 5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula IV Charge (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l- one in water and add adjust pH to less than 1.0 by using dilute HC1 solution (50%) (140 to 150 ml). Stir the reaction mass for 2 hr at 20 - 45°C. Filter the reaction mass and washed with water.
  • Example 4 Process for the purification of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV (Impurity profile, yield, process time etc..)
  • Mobile phase A mixture of 600volume of water, 400 volume of methanol and I volume of triethyl amine, adjust the pH to 3.0with orthophosphate acid and filter.
  • Standard Solution 0.5mg/mL of Stage-1 standard in mobile phase.
  • Sample solution 0.5mg7mL of sample in mobile phase.
  • the inventors have observed that during process of hydrogenation of (E)-2-(( 1 -benzylpiperidin- 4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-l H-inden-1 -one to 2-((l-benzylpiperidin-4- yl)methyl)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one formation of an impurity at 0.29-0.32 RRT occurs about 10.0% to 5.0% (figure 17).
  • the amount of impurity formation varies depending upon reaction conditions, amount of solvent, nature of solvent used. It is advantageous to remove impurity at final stage and further it gets difficult to remove.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention relates to a process for preparation of 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one Hydrochloride (Donepezil hydrochloride) of formula I. The present invention also relates to a intermediates of Donepezil, (E)-2-((1-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one HCl compound of formula V which is further converted to highly pure intermediates of Donepezil, (E)-2-((1-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one compound of formula IV.

Description

Title AN IMPROVED PROCESS OF DONEPEZIL HYDOCHLORIDE
FIELD OF THE INVENTION
The present invention relates to a process for preparation of 2-((l-benzylpiperidin-4-yl) methyl)-5,6-dimethoxy- 2,3-dihydro- 1H-inden- 1 -one Hydrochloride (Donepezil hydrochloride) of formula I . The present invention also relates to a intermediates of Donepezil, (E)-2-(( 1 -benzylpiperidin-4-yl) methylene)- 5,6-dimethoxy- 2,3-dihydro- 1H- inden-l-one hydrochloride compound of formula V which is further converted to highly pure intermediates of Donepezil, (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- dihydro- 1H-inden- 1 -one compound of formula IV.
BACKGROUND OF THE INVENTION
Donepezil hydrochloride is a useful memory enhancer introduced by the Japanese pharmaceutical company Eisai. Its preparation was described in patent no. EP 296560. In this patent Donepezil was produced by reaction of 5,6-dimethoxy- 1 -indanone with l-benzyl-4- formylpiperidine in the presence of a strong base, such as lithium diisopropylamide followed by reduction of the double bond.
Organic Process Research & Development 2008, 12, 731-735 describes process for the synthesis of Donepezil. According to this article, condensation of 1 -benzylpiperidine -4- carboxaldehyde (2) 5,6-dimethoxy indanone (3) in the presence of a strong base such as n-butyl lithium and diisopropylamine in hexamethyl phosphoric amide (HMPA) under inert atmosphere at -78 °C, and finally catalytic reduction of the double bond compound 4 with 10% Pd/C in tetrahydrofuran (THF) furnished donepezil free base (Figure 1, Path A). This process suffered from several disadvantages: (a) use of hazardous and pyrophoric reagents such as n-butyl- lithium, (b) unacceptable process solvents such as hexane and HMPA, (c) the requirement for special equipment to attain the lower temperatures required for the condensation of 2 and 3 and (d) purification of 4 and free base of 1 by column chromatography.
Figure imgf000003_0001
Patent application EP 711756 describes the preparation of Donepezil by reaction of 5,6- dimethoxy- 1 -indanone with pyridin-4-aldehyde to give 5,6-dimethoxy-2-(pyridin-4- yl)methylene indan-l-one further the reaction with benzyl bromide afforded 1 -benzyl -4-(5, 6- dimethoxyindan-l-on-2-ylidene)methylpyridinium bromide. Hydrogenation in the presence of platinum oxide to obtain Donepezil.
In view of the above, the prior art processes are time consuming and difficult to carry out as they involve many steps. Most of the prior art approaches are not suitable from commercial point of view because the desired product is not obtained in high purity and requires purification by tedious and cumbersome purification processes.
The inventors have observed that during the condensation reaction of 5,6-dimethoxy-2,3- dihydro- 1 H-i nden- 1 -one compound of formula-II,
Figure imgf000004_0001
with 1 -benzylpiperidine -4-carbaldehyde compound of formula-III,
Figure imgf000004_0002
for the preparation of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden-l-one compound of formula IV
Figure imgf000004_0003
formation of an impurity at 0.47-0.49 RRT occurs about 15% to 10%. The amount of impurity formation varies depending upon reaction conditions, amount of solvent, nature of solvent used. It is advantageous to remove impurity at this stage; otherwise it hinders the process of hydrogenation of (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5 ,6-dimethoxy-2,3-dihydro- 1H- inden-l-one compound of formula IV and further it gets converts to hydrochloride in the presence of hydrochloric acid, hence difficult to remove. Further hydrogenation is required to reduce the double bond of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- dihydro- 1 H-inden-1 -one compound of formula IV, the inventors have further found that during hydrogenation of compound of formula VI in the presence of palladium catalyst impurity is generated at RRT 0.29-0.32. Once the impurity is generated at RRT 0.29-0.32 in the reaction mixture it is difficult to remove. An additional step for purification of impurity is required to obtain purified desired compound. To achieve a high efficiency of the reaction for industrial synthesis of donepezil, it is necessary to minimize the formation of the impurities and improve the yields.
Thus, the present invention provides an efficient and industrially advantageous process for the preparation of highly pure donepezil hydrochloride in high yields. SUMMARY OF THE INVENTION
Accordingly, in one aspect, present invention provides an improved process for the preparation of highly pure 2-((l-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2, 3 -dihydro- 1H-inden-l -one
Hydrochloride (Donepezil HC1) of formula I
Figure imgf000005_0002
comprises: a) condensation reaction of 5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula-II with l-benzylpiperidine-4-carbaldehyde compound of formula-III to obtain of (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1 H-inden- 1 - one compound of formula IV ;
Figure imgf000005_0001
b) treating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH- inden-l-one compound of formula IV with acid and converting to pharmaceutically acceptable salts and isolating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride compound of formula V; c) treating the compound of formula V with base to (E)-2-((l-benzylpiperidin-4- yl)methylene)-5 ,6-dimethoxy-2, 3 -dihydro- 1 H-inden- 1 -one compound of formula IV ; d) hydrogenating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden-l-one compound of formula IV in presence of palladium catalyst and an organic solvent; e) treating the donepezil base with acid and converting to pharmaceutically acceptable salts.
Figure imgf000006_0001
In another aspect, present invention provides a process for the preparation of (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one compound of formula IV comprises:
Figure imgf000006_0002
a) condensation reaction of 5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula-II
Figure imgf000006_0003
with 1 -benzylpiperidine -4-carbaldehyde compound of formula-III;
Figure imgf000006_0004
in the presence of phase transfer catalyst and base with methylene dichloride. b) treating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1H- inden-l-one compound of formula IV with acid and converting to pharmaceutically acceptable salts and isolating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride compound of formula V; c) treating the compound of formula V with base to (E)-2-((l-benzylpiperidin-4- yl)methylene)-5 ,6-dimethoxy-2, 3 -dihydro- 1 H-inden- 1 -one compound of formula IV ; d) washing with ketone solvent. In another aspect, present invention provides a process for the purification of E’)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one compound of formula IV to remove impurity comprising a) treating the reaction mixture with acid wherein pH is below 1.0; b) treating the reaction mixture with base wherein pH is greater than 11.0; c) repeat step (a) and step (b) up to impurity at 0.49 RRT NMT 0.3 %; d) washing with ketone solvent at 55 -65 °C;
In another aspect, present invention provides a process for the preparation of 2-((l- benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one Hydrochloride (Donepezil hydrochloride) of formula I comprises:
Figure imgf000007_0001
a) hydrogenating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden-l-one compound of formula IV in presence of Palladium catalyst and an organic solvent; b) treating the donepezil base with acid and converting to pharmaceutically acceptable salts.
Figure imgf000007_0002
c) dissolve in alcoholic solvent; d) precipitated 2-(( l-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-lH-inden- 1-one Hydrochloride (Donepezil hydrochloride) of formula I with diisopropyl ether.
Accordingly, in another aspect, present invention provides an isolated compound (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-l 1H-inden-1 -one Hydrochloride compound of formula V
Figure imgf000008_0001
DETAILED DESCRIPTION OF DRAWINGS:
FIGURE 1: is a HPLC chromatograph of result of analysis of Crude (E)-2-(( 1 -benzylpiperidin- 4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
FIGURE 2: is a HPLC chromatograph of result of analysis of Purification in Ethyl acetate of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
FIGURE 3 : is a HPLC chromatograph of result of analysis of Purification in Diisopropyl ether of (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one, Compound of Formula IV.
FIGURE 4: is a HPLC chromatograph of result of analysis of Purification in Isopropyl acetate (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
FIGURE 5: is a HPLC chromatograph of result of analysis of Crude of Example 2 (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one, Compound of Formula IV.
FIGURE 6: is a HPLC chromatograph of result of analysis of Ist Acid treatment of Example 2 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
FIGURE 7: is a HPLC chromatograph of result of analysis of Ist Base treatment of Example 2 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV.
FIGURE 8: is a HPLC chromatograph of result of analysis of IInd Acid treatment of Example 2 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one,
Compound of Formula IV. FIGURE 9: is a HPLC chromatograph of result of analysis of IInd Base treatment of Example
2 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one, Compound of Formula IV.
FIGURE 10: is a HPLC chromatograph of result of analysis of treatment with Acetone of Example 2 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l- one, Compound of Formula IV.
FIGURE 11: is a HPLC chromatograph of result of analysis of Crude of Example 3 (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one, Compound of Formula IV.
FIGURE 12: is a HPLC chromatograph of result of analysis of Ist Acid treatment of Example
3 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one, Compound of Formula IV.
FIGURE 13: is a HPLC chromatograph of result of analysis of Ist Base treatment of Example
4 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one, Compound of Formula IV.
FIGURE 14: is a HPLC chromatograph of result of analysis of IInd Acid treatment of Example 3 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one,
Compound of Formula IV.
FIGURE 15: is a HPLC chromatograph of result of analysis of IInd Base treatment of Example 3 (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one,
Compound of Formula IV.
FIGURE 16: is a HPLC chromatograph of result of analysis of treatment with Acetone of Example 3 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l- one, Compound of Formula IV.
FIGURE 17: is a HPLC chromatograph of result of analysis of crude 2-(( 1 -benzylpiperidin-4- yl)methyl)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one Compound of Formula I
FIGURE 18: is a HPLC chromatograph of result of analysis of purified 2-(( 1 -benzylpiperidin- 4-yl) methyl)-5,6-dimethoxy- 2,3-dihydro-lH-inden-l-one Hydrochloride (Donepezil Hydrochloride) of formula I
DETAILED DESCRIPTION OF THE INVENTION As used herein, the terms below have the meanings indicated.
The singular forms "a," "an," and "the" may refer to plural articles unless specifically stated otherwise.
The term "about," as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term "about" should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, taking into account significant figures.
In the first embodiment the present invention provides an improved process for the preparation of highly pure 2-((l-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2, 3 -dihydro- 1H-inden-l -one Hydrochloride (Donepezil HC1) of formula I
Figure imgf000010_0001
comprises: a) condensation reaction of 5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula-II with l-benzylpiperidine-4-carbaldehyde compound of formula-III to obtain of (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1 H-inden- 1 - one compound of formula IV ;
Figure imgf000010_0002
b) treating (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2, 3 -dihydro- 1 H- inden- 1 -one compound of formula IV with acid and converting to pharmaceutically acceptable salts and isolating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride compound of formula V;
Figure imgf000011_0001
c) treating the compound of formula V with base to (E)-2-(( 1 -benzyl pi peridi n-4- yl)methylene)-5,6-dimethoxy-2, 3 -dihydro- IH-inden-l -one compound of formula IV;
Figure imgf000011_0002
d) hydrogenating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden-l-one compound of formula IV in presence of Palladium catalyst and an organic solvent; e) treating the Donepezil base with acid and converting to pharmaceutically acceptable salts.
Figure imgf000011_0003
According to another embodiment, there is provided a process for the preparation of (E)-2-(( 1 - benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-l H-inden-1 -one compound of formula IV in high purity and better yields by the condensation of 5,6-dimethoxy-2,3-dihydro- IH-inden-l-one compound of formula II
Figure imgf000011_0004
with 1 -benzylpiperidine -4-carbaldehyde compound of formula III;
Figure imgf000012_0002
to obtain of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2, 3 -dihydro- 1H-inden- 1-one compound of formula IV, in the presence of phase transfer catalyst and base with methylene dichloride as solvent. Specifically the reaction is conducted at 25°C-70°C in methylene dichloride for about 2-10 hours for completion of reaction.
The (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5 ,6-dimethoxy-2, 3 -dihydro- 1 H-i nden- 1 -one compound of formula IV was further treated with acid and isolated (E)-2-(( 1 -benzylpiperidin- 4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-l H-inden-1 -one Hydrochloride compound of formula V which was purified to remove impurity.
According to above embodiment, phase-transfer catalyst is a quaternary ammonium salt such as tetra-n-butylammonium chloride, tetra-n-butylammonium bromide (TBAB), and methyltri-n- octylammonium chloride. Most preferabl phase-transfer catalyst is Tetrabutyl ammonium halides, such as tetrabutylammonium bromide (TBAB).
According to above embodiment, organic solvent comprises ethers, alcohols, chlorinated hydrocarbons, esters, ketones, hydrocarbons, polar aprotic solvents, water and mixtures thereof.
According to another embodiment, there is provided a process for the preparation (E)-2-((l- benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1 H-inden-1 -one Hydrochloride compound of formula V comprises treating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one compound of formula IV with acid and converting to pharmaceutically acceptable salts and isolating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride compound of formula V.
Figure imgf000012_0001
According to another embodiment, the isolated (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride compound of formula V was treated with base to obtain (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH- inden-l-one compound of formula IV.
Figure imgf000013_0001
According to above embodiment, acid is selected from hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid or boric acid and base is selected from sodium hydroxide and potassium hydroxide.
According to above embodiment, is further purified with (E)-2-((l-benzylpiperidin-4- yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula IV ketone solvent, wherein ketone solvent are 2-pentanone, 3-pentanone, 2-hexanone, methyl isobutyl ketone, 2-heptanone, 3-heptanone, 4-heptanone, diisobutyl ketone, mesityl oxide, phorone, 2- octanone, cyclohexanone, methylcyclohexanone, isophorone, 2,4-pentanedione or 2,5- hexanedione, acetone or methyl ethyl ketone.
The purified (£’)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2, 3 -dihydro- IH-inden- 1-one compound of formula IV is isolated in high purity greater than 99.5% preferably greater than 99.8%.
According to another embodiment, there is provided a process for the preparation of highly pure 2-(( 1 -benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride (Donepezil HC1) of formula I which includes hydrogenating (E)-2-(( 1 - benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l -one compound of formula IV, in the presence of palladium catalyst to produce and isolating the substantially pure donepezil or a salt thereof. Specifically hydrogenation of (E)-2-((l-benzylpiperidin-4- yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1 H-inden-1 -one compound of formula IV is carried out using palladium catalyst in an organic solvent at 0-50° C. preferably at 25-40° C. under 1-5 atmospheric pressure preferably at 4 atmospheric pressure. The organic solvent can be selected from solvent comprises ethers, alcohols, chlorinated hydrocarbons, esters, ketones, hydrocarbons, polar aprotic solvents, water and mixtures thereof and preferably ethyl acetate is used.
According to embodiment, hydrogenation reactions is carried out using palladium catalyst and it was found that using palladium catalyst with solvent, impurity at RRT 0.32 is substantial controlled depending upon the solvent system used during the reaction. Palladium catalyst can be selected from Palladium oxide, Palladium on carbon and preferably Palladium on carbon is used. The reaction can be accomplished at 0-50°C and preferably at 25-35°C. The progress of the reaction is monitored by high performance liquid chromatography (HPLC) and the reaction is stirred till the unreacted Formula IV not more than 0.8%. The reaction mixture is filtered to recover the catalyst. The filtrate is concentrated and crude donepezil is dissolved in aq. Solution of Acid preferably HC1 and washed with organic solvent preferably Ethyl acetate. The aqueous layer is treated with methylene chloride (MDC).
The resulting mixture is concentrated and the product obtained is recrystallized from methanol and diisopropyl ether to obtain highly pure donepezil hydrochloride having purity greater than 99.2% preferably greater than 99.9%.
Major advantages realized in the present invention are high purity and high yields. The formation of impurity at RRT 0.29-0.32 has been restricted by making use of Palladium catalyst with solvent system of methylene chloride and methanol. This avoids the use of tedious and cumbersome technique i.e. chromatographic purification as additional step of purification.
The stage I impurity is removed from (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one Hydrochloride compound of formula V by and further treatment with acid and base of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- di hydro- 1H-inden- 1 -one compound of formula IV.
Figure imgf000015_0001
The present invention is further illustrated by the following examples which are provided merely to be exemplary of the inventions and is not intended to limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLES
EXAMPLE 1 : Preparation of (E')-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-
2,3-dihydro- 1 //-inden- 1 -one compound of formula IV 5.6-dimethoxy-2,3-dihydro-lH-inden-l-one (100g) was dissolved in methylene dichloride (350ml) followed by addition of TBAB (10.0g) cooled to 15 ± 5 temperature, add sodium hydroxide solution 250 ml. l-benzylpiperidine-4-carbaldehyde (126.8g) solution in dichloromethane was added to reaction mass below 20 °C. The temperature of the reaction mass was gradually raised to 40 to 45 °C and was stirred for 6 hours. The reaction mass was concentrated under vacuum. The slurry was filtered and the product was washed with water to give (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1H-inden- 1 -one. Result: Dry wt. 195 g, HPLC purity: 96.937%, Impurity at RRT 0.47 - 0.49: 1.275 % and Impurity at RRT 1.73 0.398 %.
EXAMPLE 2: Preparation and Purification of (E')-2-((l-benzylpiperidin-4-yl)methylene)-
5.6-dimethoxy-2,3-dihydro-lH-inden- 1-one compound of formula IV
To reaction mass from example 1 (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy- 2,3-dihydro-lH-inden-l -one was charged in water and treated with Diluted HC1 solution (140 To 150 ml ) pH adjusted to below 1.0. (Preparation of Diluted HC1 : 70 ml HC1 35% + 70 ml Process Water.). The reaction mixture was stirred for 2 to 4hr at 20-45°C and after completion of reaction, the reaction mass filtered and washed with DM water. The reaction mass was treated with around 10 % NaOH Solution (200 ml To 220 ml ) and pH was adjusted to not less than 11.5, [Preparation of 10 % NaOH Solution : 20 gm NaOH dissolved in 200 ml of Process Water] The reaction mixture was stirred for 2 to 4hr at 20-45°C and after completion of reaction, the reaction mass was filtered and washed with water. The process of acid and base treatment was repeated up to unknown impurity at 0.47-0.49 RRT was NMT 0.3 %. After the completion of acid base treatment reaction mass was treated with acetone. The temperature of the reaction mass was gradually raised to 55 to 65°C and was stirred for 0.5 hours. Cooled to 20 to 30 °C which was filtered with acetone to obtain 142 to 180 gm of (E)-2-((l-benzylpiperidin^- yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1 H-inden-1 -one having a purity of 99.8% by HPLC and % Yield : 91.84%.
EXAMPLE 3: Preparation and Purification of (E,)-2-((l-benzylpiperidin-4-yl)methylene)- 5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula IV Charge (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l- one in water and add adjust pH to less than 1.0 by using dilute HC1 solution (50%) (140 to 150 ml). Stir the reaction mass for 2 hr at 20 - 45°C. Filter the reaction mass and washed with water. Charge the obtained solid in 10% Sodium hydroxide solution (200 ml to 220 ml) and pH adjusted to not less than 11.5. Stir the reaction mass for 2 - 4 hr at 20 - 45°C. Filter the reaction mass and washed with water. The acid base purification treatment repeated till the unknown impurity at RRT 0.47 - 0.49 is NMT 0.3%. The obtained solid after acid base treatment is treated with acetone. Raise temperature of reaction mass to 55 - 65°C and maintained for 0.5 hr. Cooled to 20 - 30°C. Stir for 0.5 hr and filter the solid and wash with acetone.
Result: Dry Wt. 160 g, HPLC: 99.8%.
Example 4: Process for the purification of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV (Impurity profile, yield, process time etc..)
The Purification of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH- inden- 1 -one, Compound of Formula IV where studied by conducting experiments of using range of solvents like Ethyl acetate, Diisopropyl ether, Isopropyl acetate, Acetone, Toluene, Dichloromethane and different mixture of solvent we have performed and observed that impurity at 0.47 RRT not removed by this solvent technique.
The inventors have observed that during process of Preparation of (E)-2-(( I -benzylpiperidin-4- yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of Formula IV formation of an impurity at 0.47-0.49 RRT occurs about 1.5% to 1.0%. The amount of impurity formation varies depending upon reaction conditions, amount of solvent, nature of solvent used. It is advantageous to remove impurity at this stage; otherwise it hinders the process of hydrogenation of (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5 ,6-dimethoxy-2, 3 -dihydro- 1 H-i nden- 1 -one compound of formula IV and further it gets converts to hydrochloride in the presence of hydrochloric acid, hence difficult to remove.
So, inventors have developed acid and base purification process, during acidic treatment impurity at 0.47 - 0.49 RRT removed easily by acid and base treatment. The purity was determined by separating a sample by high performance liquid chromatography (HPLC) under the following conditions, and calculating the area percentage thereof of each peak.
HPLC Procedure:
Mobile phase: A mixture of 600volume of water, 400 volume of methanol and I volume of triethyl amine, adjust the pH to 3.0with orthophosphate acid and filter. Standard Solution: 0.5mg/mL of Stage-1 standard in mobile phase.
Sample solution: 0.5mg7mL of sample in mobile phase.
Chromatographic system:
Mode: LC
Detector: U V 230nm
Column: Inertsil ODS-3V (250 X 4.6mm), 5μ Flow; ImL/min.
Injection Volume: 20μL
Retention time of Stage-I: about 17.2min
The comparative data of crude and purified of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one compound of formula IV by using different solvents and acid and base treatment.
Removal of impurity at RRT 0.47 - 0.49 from (£’)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 17/-inden- 1 -one compound of formula IV by using different organic solvents and is tabulated as below in table 1
Table 1:
Figure imgf000018_0001
Figure imgf000019_0001
Removal of impurity at RRT 0.47 - 0.49 from (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula IV by using different acid base treatment and is tabulated as below Table 2 as per example 2
Table 2
Figure imgf000019_0002
Removal of impurity at RRT 0.47 - 0.49 from (£’)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro- 17/-inden- 1 -one compound of formula IV by using acid base treatment and is tabulated as below Table 3 as per example 3
Figure imgf000019_0003
Advantages of the process for the purification of (E)-2-((l-benzylpiperidin-4- yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one, Compound of Formula IV (Impurity profile, yield, process time etc..)
> Compound of Formula IV is purified by Acid and Base purification procces.
> No any organic solvent was suitable to purge the impurity at RRT 0.47 to 0.49%. > Excellent yield is obtained by acid and base purification.
EXAMPLE 8 : Preparation of 2-((l-benzylpiperidin-4-yl) methyl)-5,6-dimethoxy- 2,3- dihydro- 1 //-inden- 1 -one Hydrochloride (Donepezil Hydrochloride) of formula I
(E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- 1 H-inden- 1 -one
(100.0 g) was taken in methylene dichloride (500 ml) and methanol (500ml) followed by addition of 5% palladium-carbon (5 g). The reaction mixture was hydrogenated at temperature 20-30°C and 1 Kg/Cm2 pressure for 1 to 2 hours. After completion of reaction, the catalyst was filtered off and filtrate was concentrated under vacuum to obtained residue. The residue was dissolved in solution of hydrochloric acid in water. Washed with ethyl acetate and extracted with dichloromethane, followed by concentration in vacuum to obtain a crystal, which was recrystallized from methanol/ diisopropyl Ether to obtain 90 g of 2-(( 1 -benzylpiperidin-4- yl)methyl)-5,6-dimethoxy-2,3-dihydro-l H-inden-1 -one Hydrochloride having purity of 99.9% by HPLC and % Yield : 81.81%.
The inventors have observed that during process of hydrogenation of (E)-2-(( 1 -benzylpiperidin- 4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-l H-inden-1 -one to 2-((l-benzylpiperidin-4- yl)methyl)-5,6-dimethoxy-2,3-dihydro-lH-inden-l-one formation of an impurity at 0.29-0.32 RRT occurs about 10.0% to 5.0% (figure 17). The amount of impurity formation varies depending upon reaction conditions, amount of solvent, nature of solvent used. It is advantageous to remove impurity at final stage and further it gets difficult to remove.
So, inventors have developed a process of treating 2-((l-benzylpiperidin-4-yl)methyl)-5,6- dimethoxy-2,3-dihydro- 1 H-inden- 1 -one with acid and purification with ethyl acetate and Methylene Dichloride further process reaction mass is treated with Methanol and Diisopropyl Ether, during acidic treatment impurity at 0.29 - 0.32 RRT is removed easily by ethyl acetate and MDC treatment wherein the impurity is impurity at 0.29-0.32 RRT after purification process is less than 0.30%. (figure 18)

Claims

We Claim,
1. An improved process for the preparation of highly pure 2-(( 1 -benzylpiperidin-4- yl)methyl)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one Hydrochloride
(Donepezil HC1) of formula I
Figure imgf000021_0001
comprises: a) condensation reaction of 5,6-dimethoxy-2,3-dihydro-lH-inden-l-one compound of formula-II with 1 -benzylpiperidine-4-carbaldehyde compound of formula-III to obtain of (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- dihydro- 1 H-inden- 1 -one compound of formula IV;
Figure imgf000021_0002
b) treating (E)-2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-
IH-inden-l-one compound of formula IV with acid and converting to pharmaceutically acceptable salts and isolating (E)-2-((l-benzylpiperidin-4- yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one Hydrochloride compound of formula V ; c) treating the compound of formula V with base to (E)-2-((l-benzylpiperidin-4- yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one compound of formula IV ; d) hydrogenating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- dihydro-lH-inden-l-one compound of formula IV in presence of palladium catalyst and an organic solvent; e) treating the donepezil base with acid and converting to pharmaceutically acceptable salts.
Figure imgf000022_0001
The improved process as claimed in claim 1, wherein palladium catalyst is preferably Palladium oxide, Palladium on carbon. The improved process as claimed in claim 1, wherein the organic solvent comprises ethers, alcohols, chlorinated hydrocarbons, esters, ketones, hydrocarbons, polar aprotic solvents, water and mixtures thereof. The improved process as claimed in claim 1 , wherein ketone solvent are 2-pentanone, 3-pentanone, 2-hexanone, methyl isobutyl ketone, 2-heptanone, 3-heptanone, 4- heptanone, diisobutyl ketone, mesityl oxide, phorone, 2-octanone, cyclohexanone, methylcyclohexanone, isophorone, 2,4-pentanedione or 2,5-hexanedione, acetone or methyl ethyl ketone. The improved process as claimed in claim 1 , wherein acid selected from hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid or boric acid. The improved process as claimed in claim 1, wherein 2-((l-benzylpiperidin-4- yl)methyl)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one Hydrochloride
(Donepezil HC1) of formula I is recrystallized from methanol and diisopropyl ether to obtain highly pure donepezil hydrochloride having purity greater than 99.2% preferably greater than 99.9%. The improved process as claimed in claim 1 , wherein condensation reaction of step (a) is conducted at 25°C-70°C in methylene dichloride for about 2-10 hours. A improved process for the preparation of (E)-2-((l-benzylpiperidin-4-yl)methylene)- 5,6-dimethoxy-2,3-dihydro-l H-inden-1 -one compound of formula IV comprises:
Figure imgf000023_0001
a) condensation reaction of 5,6-dimethoxy-2,3-dihydro-lH-inden-l -one compound of formula-II
Figure imgf000023_0002
with 1 -benzylpiperidine -4-carbaldehyde compound of formula-III;
Figure imgf000023_0003
in the presence of phase transfer catalyst and base with methylene dichloride. b) treating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-lH- inden-l-one compound of formula IV with acid and converting to pharmaceutically acceptable salts and isolating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6- dimethoxy-2,3-dihydro-l H-inden-1 -one Hydrochloride compound of formula V; c) treating the compound of formula V with base to (£)-2-((l-benzylpiperidin-4- yl)methylene)-5,6-dimethoxy-2, 3 -dihydro- IH-inden-l -one compound of formula IV; d) washing with ketone solvent. The improved process as claimed in claim 7, wherein phase-transfer catalyst is a quaternary ammonium salt such as tetra-n-butylammonium chloride, tetra-n- butylammonium bromide (TBAB), and methyltri-n-octylammonium chloride The improved process as claimed in claim 8, wherein process for the purification of E)-
2-(( 1 -benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro- IH-inden- 1 -one compound of formula IV to remove impurity comprising a) treating the reaction mixture with acid wherein pH is 0.1 to 6.0; b) treating the reaction mixture with base wherein pH is greater than 11.0; c) repeat step (a) and step (b) up to impurity at 0.47 - 0.49 RRT NMT 0.3 %; d) washing with ketone solvent at 55-65°C. The improved process as claimed in claim 10, wherein ketone solvent are 2-pentanone,
3-pentanone, 2-hexanone, methyl isobutyl ketone, 2-heptanone, 3-heptanone, 4- heptanone, diisobutyl ketone, mesityl oxide, phorone, 2-octanone, cyclohexanone, methylcyclohexanone, isophorone, 2,4-pentanedione or 2,5-hexanedione, acetone or methyl ethyl ketone. The improved process as claimed in claim 10, wherein acid selected from hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid or boric acid. The improved process as claimed in claim 10, wherein base selected from sodium hydroxide and potassium hydroxide A process for the preparation of 2-((l-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3- dihydro-lH-inden-l-one Hydrochloride (Donepezil hydrochloride) of formula I comprises:
Figure imgf000024_0001
a) hydrogenating (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- dihydro- 1 H-inden- 1 -one compound of formula IV in presence of Palladium catalyst and an organic solvent; b) treating the donepezil base with hydrochloric acid (HC1) and converting to pharmaceutically acceptable salts and dissolving in water;
Figure imgf000025_0001
c) extracting impurity at 0.29 - 0.32 RRT by washing with ethyl acetate repeat washing up to impurity at 0.29 - 0.32 RRT NMT 0.3%; d) extracting 2-((l-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-lH- inden-l-one Hydrochloride (Donepezil hydrochloride) of formula I with Methylene Dichloride and distilling; e) residue of 2-((l-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-lH- inden-l-one Hydrochloride (Donepezil hydrochloride) of formula I is crystallized with methanol and diisopropyl ether having purity greater than 99.2% to 99.9%. The improved process as claimed in claim 14, wherein organic solvent comprises ethers, alcohols, chlorinated hydrocarbons, esters, ketones, hydrocarbons, polar aprotic solvents, water and mixtures thereof. An isolated compound (E)-2-((l-benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3- dihydro-lH-inden-1 -one Hydrochloride compound of formula V
Figure imgf000025_0002
PCT/IN2021/051042 2020-10-30 2021-10-30 An improved process of donepezil hydochloride WO2022091141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021047530 2020-10-30
IN202021047530 2020-10-30

Publications (1)

Publication Number Publication Date
WO2022091141A1 true WO2022091141A1 (en) 2022-05-05

Family

ID=81382066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/051042 WO2022091141A1 (en) 2020-10-30 2021-10-30 An improved process of donepezil hydochloride

Country Status (1)

Country Link
WO (1) WO2022091141A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191610A1 (en) * 2006-02-16 2007-08-16 Mahesh Nagarimadugu Process for the preparation of donepezil hydrochloride
WO2011051957A2 (en) * 2009-10-30 2011-05-05 Neuland Laboratories Ltd. A process for the preparation of donepezil hydrochloride
CN111100062A (en) * 2019-12-30 2020-05-05 山东罗欣药业集团恒欣药业有限公司 Synthesis method of donepezil hydrochloride

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191610A1 (en) * 2006-02-16 2007-08-16 Mahesh Nagarimadugu Process for the preparation of donepezil hydrochloride
WO2011051957A2 (en) * 2009-10-30 2011-05-05 Neuland Laboratories Ltd. A process for the preparation of donepezil hydrochloride
CN111100062A (en) * 2019-12-30 2020-05-05 山东罗欣药业集团恒欣药业有限公司 Synthesis method of donepezil hydrochloride

Similar Documents

Publication Publication Date Title
EP1939178B1 (en) Process for producing 1-benzyl-4-[(5,6-dimethoxy-1indanon)-2-yl]methylpiperidine or hydrochloride thereof
EP1960357A2 (en) Synthesis and preparations of intermediates and polymorphs thereof useful for the preparation of donepezil hydrochloride
US20020013500A1 (en) Process for producing trifluoromethylbenzylamines
US8378106B2 (en) Method for preparing argatroban monohydrate and a process for its synthesis
WO2007108011A2 (en) Process for the preparation of highly pure donepezil
WO2005044805A1 (en) A novel process for preparing donepezil and its derivatives
EP2278970B1 (en) Process for the preparation of donepezil hydrochloride
WO2022091141A1 (en) An improved process of donepezil hydochloride
US6140507A (en) Method for debenzylation of dibenzylbiotin
EP1770084B1 (en) Method for producing (z)-1-phenyl-1-diethylaminocarbonyl-2-aminomethyl cyclopropane hydrochloride
JP5749260B2 (en) Method for producing neramexane
US7795438B2 (en) Processes for producing 1-benzyl-4-[(5,6-dimethoxy-1indanon)-2-yl]methylpiperidine and hydrochloride
US20120253051A1 (en) Process for the preparation of ropinirole and salts thereof
CN111100062A (en) Synthesis method of donepezil hydrochloride
US20060264637A1 (en) Preparation of paroxetine hydrochloride hemihydrate
US20140371457A1 (en) Process for production of quinuclidine compounds
WO2005076749A2 (en) A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine
JP4072341B2 (en) Method for producing ethyl group-containing alicyclic tertiary alcohol
US8455692B2 (en) Process for resolution of 1-(3-hydroxyphenyl)-2-methylamino ethanol
CN109311811B (en) Process for preparing 4- (piperidine-4-yl) morpholine
WO2008117123A2 (en) Process for preparing donepezil hydrochloride polymorphic form i
JP3948176B2 (en) Caprolactam production method
CA2588777C (en) Novel processes for preparing sertraline hydrochloride crystalline forms
CN114685509A (en) Preparation method of Reidesciclovir intermediate or hydrochloride thereof
WO2019142901A1 (en) Method for producing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21885556

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21885556

Country of ref document: EP

Kind code of ref document: A1